- Report
- May 2024
- 135 Pages
Global
From €6214EUR$6,499USD£5,201GBP
- Report
- June 2024
- 200 Pages
Global
From €7601EUR$7,950USD£6,363GBP
- Report
- January 2022
- 60 Pages
Global
From €3777EUR$3,950USD£3,161GBP
- Report
- January 2022
- 200 Pages
Global
From €7171EUR$7,500USD£6,002GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1912EUR$2,000USD£1,601GBP
- Report
- August 2022
Global
From €755EUR$790USD£632GBP
- Report
- November 2022
- 77 Pages
Global
From €1912EUR$2,000USD£1,601GBP
Sanfilippo Syndrome is a rare genetic disorder that affects the body's ability to break down certain sugars. It is a type of lysosomal storage disorder, and is also known as Mucopolysaccharidosis III. Immune disorders drugs are used to treat Sanfilippo Syndrome, and they work by replacing the missing enzyme that is responsible for breaking down the sugars. These drugs can help to reduce the symptoms of the disorder, and slow down the progression of the disease.
The Sanfilippo Syndrome Drug market is a relatively small market, with only a few companies offering treatments. These companies are focused on developing treatments that can help to improve the quality of life for those affected by the disorder. Some of the companies in the market include BioMarin Pharmaceuticals, Ultragenyx Pharmaceuticals, and Audentes Therapeutics. Show Less Read more